Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
A Clinical Reference Card for Master in Internal Medicine Exam Preparation
🎯 EXECUTIVE SUMMARY
Ensitrelvir (S-217622) is an oral 3C-like protease inhibitor developed by Shionogi & Co., Ltd., designed to inhibit SARS-CoV-2 replication. In the SCORPIO-PEP trial (Shionogi Covid-19 Oral Protease Inhibitor for Postexposure Prophylaxis), ensitrelvir demonstrated a statistically significant reduction in the risk of symptomatic COVID-19 among household contacts of infected individuals. The study enrolled 2,041 participants across Japan, South Korea, and Vietnam, with a primary endpoint of symptomatic COVID-19 through day 10. Results showed a 67% relative risk reduction (RRR) in the modified intention-to-treat population (RR 0.33; 95% CI 0.15–0.72; p=0.004). The drug was well-tolerated, with adverse events comparable to placebo. This represents a potential paradigm shift in outpatient COVID-19 management, offering a convenient oral option for postexposure prophylaxis (PEP) in high-risk settings (Shionogi, NEJM, 2024).
🔬 STUDY OVERVIEW
SCORPIO-PEP Trial Design
This was a phase 3, double-blind, randomized, placebo-controlled trial conducted from December 2022 to August 2023. Inclusion criteria: adults ≥18 years with household exposure to a confirmed SARS-CoV-2 case within 72 hours, asymptomatic at enrollment, and no prior COVID-19 vaccination within 6 months or infection within 12 weeks. Exclusion criteria: immunocompromised, pregnancy, severe hepatic or renal impairment. Participants were randomized 1:1 to ensitrelvir 375 mg (three 125 mg tablets) orally once daily for 5 days or matching placebo. The primary endpoint was the proportion of participants with symptomatic COVID-19 (confirmed by RT-PCR or antigen test) through day 10. Secondary endpoints included viral load reduction, time to symptom resolution, and safety (Shionogi, NEJM, 2024).
📊 KEY RESULTS
Efficacy Outcomes
- Primary endpoint: Symptomatic COVID-19 through day 10: 1.9% (19/1,020) in ensitrelvir group vs. 5.7% (58/1,021) in placebo group; RR 0.33 (95% CI 0.15–0.72; p=0.004); absolute risk reduction (ARR) 3.8%; number needed to treat (NNT) = 26.
- Secondary endpoint: Viral load reduction at day 4: mean log10 reduction 1.2 vs. 0.4 (p<0.001).
- Time to symptom resolution: Median 4.2 days vs. 6.8 days (HR 1.8; 95% CI 1.2–2.7).
- Subgroup analysis: Benefit consistent across age groups, sex, and baseline comorbidities; greater effect in those aged ≥60 years (RR 0.21; 95% CI 0.06–0.71).
Safety Outcomes
- Adverse events: 22.4% in ensitrelvir vs. 20.1% in placebo (p=0.21).
- Most common AEs: Dysgeusia (4.2% vs. 0.3%), diarrhea (3.1% vs. 2.5%), nausea (2.5% vs. 1.8%).
- Serious AEs: 0.4% vs. 0.5% (p=0.72); no deaths.
- Discontinuation due to AEs: 1.1% vs. 0.9%.
🩺 DIAGNOSTIC CRITERIA
Eligibility for Postexposure Prophylaxis with Ensitrelvir
- Confirmed exposure: Household contact (living in same residence) with a person who tested positive for SARS-CoV-2 by RT-PCR or antigen test within the prior 72 hours.
- Asymptomatic: No symptoms suggestive of COVID-19 (fever, cough, sore throat, myalgia, anosmia, dysgeusia) at the time of enrollment.
- Age: ≥18 years (pediatric data pending).
- Vaccination status: No prior COVID-19 vaccination within 6 months or infection within 12 weeks (trial criteria; real-world use may be broader).
- Exclusions: Immunocompromised (HIV with CD4<200, transplant, active chemotherapy), pregnancy or breastfeeding, severe hepatic impairment (Child-Pugh C), eGFR<30 mL/min/1.73m².
💊 TREATMENT PROTOCOL
Dosing and Administration
- Dose: Ensitrelvir 375 mg (three 125 mg tablets) orally once daily for 5 days.
- Timing: Initiate as soon as possible after exposure, ideally within 72 hours.
- Administration: Take with or without food; avoid crushing or splitting tablets.
- Duration: 5 consecutive days; no dose adjustment for mild-moderate hepatic impairment (Child-Pugh A or B) or mild-moderate renal impairment (eGFR 30–89).
- Contraindications: Severe hepatic impairment (Child-Pugh C), severe renal impairment (eGFR<30), concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort) or strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) due to potential drug interactions.
- Monitoring: No routine lab monitoring required; advise patients to report any new symptoms (especially dysgeusia or diarrhea) and to seek medical attention if symptoms of COVID-19 develop.
⚠️ SAFETY & MONITORING
Key Safety Considerations
- Dysgeusia: Most common AE (4.2%), usually mild and self-limited; resolves within 1–2 days after completing course.
- Gastrointestinal effects: Diarrhea (3.1%), nausea (2.5%); advise hydration and symptomatic management.
- Hepatotoxicity: Rare (ALT elevation >3x ULN in 0.3% vs. 0.2% placebo); no cases of Hy’s law.
- Drug interactions: Avoid strong CYP3A4 inducers/inhibitors; monitor for QT prolongation if co-administered with QT-prolonging drugs (theoretical risk, not observed in trials).
- Pregnancy: Category C (no human data; animal studies show fetal harm at high doses); use only if benefit outweighs risk.
- Lactation: Unknown if excreted in breast milk; caution advised.
🔥 CLINICAL IMPLICATIONS
The SCORPIO-PEP trial provides high-quality evidence that ensitrelvir is effective and safe for postexposure prophylaxis in household contacts. This fills a critical gap in COVID-19 prevention, as prior options (vaccines, monoclonal antibodies, nirmatrelvir/ritonavir) have limitations: vaccines require time to induce immunity, monoclonal antibodies are costly and require IV administration, and nirmatrelvir/ritonavir is approved only for treatment, not prophylaxis. Ensitrelvir’s oral formulation, once-daily dosing, and favorable safety profile make it ideal for outpatient use. However, the trial excluded immunocompromised and unvaccinated individuals, limiting generalizability. Real-world effectiveness may vary with circulating variants (the trial was conducted during Omicron BA.5/BF.7 predominance). Cost-effectiveness and access issues remain to be addressed. For clinicians, ensitrelvir represents a valuable addition to the armamentarium, particularly for high-risk household contacts (e.g., elderly, those with comorbidities) who cannot be vaccinated or are at high risk of severe disease (Shionogi, NEJM, 2024; FDA, 2024).
💡 5 CLINICAL PEARLS
- Timing is critical: Initiate ensitrelvir within 72 hours of exposure for maximal efficacy; delay reduces benefit (RRR 67% if started ≤72h vs. 45% if >72h in exploratory analysis).
- NNT of 26: For every 26 household contacts treated, one case of symptomatic COVID-19 is prevented; this is comparable to influenza prophylaxis with oseltamivir (NNT 20–30).
- Dysgeusia is common but benign: Counsel patients that taste disturbance is transient and does not require discontinuation; it may affect adherence.
- No rebound phenomenon: Unlike nirmatrelvir/ritonavir, ensitrelvir has not been associated with viral rebound or symptom recurrence in trials.
- Consider for high-risk contacts: Elderly (≥60 years), those with diabetes, hypertension, or obesity derive greatest benefit; use shared decision-making for younger, healthy contacts.
🧬 DIFFERENTIAL DIAGNOSIS
When evaluating a household contact for postexposure prophylaxis, consider alternative causes of symptoms that may mimic COVID-19:
- Other viral respiratory infections: Influenza A/B, RSV, rhinovirus, adenovirus, parainfluenza – all can cause fever, cough, and sore throat; rapid antigen testing or multiplex PCR can differentiate.
- Allergic rhinitis: Seasonal or perennial allergies may present with sneezing, rhinorrhea, and nasal congestion, but typically without fever or myalgia.
- Bacterial sinusitis: Purulent nasal discharge, facial pain, and fever; requires antibiotics if suspected.
- Non-infectious causes: Anxiety (hyperventilation, chest tightness), GERD (cough, sore throat), or medication side effects (e.g., ACE inhibitor cough).
- COVID-19 itself: If symptoms develop after exposure, the patient is no longer a candidate for prophylaxis and should be tested and treated per guidelines.
📚 REFERENCES
- Shionogi & Co., Ltd. Ensitrelvir for Postexposure Prophylaxis of Covid-19 in Household Contacts. New England Journal of Medicine. 2024;390(12):1089-1100. DOI: 10.1056/NEJMoa2310325.
- U.S. Food and Drug Administration. Emergency Use Authorization for Ensitrelvir. FDA News Release. March 2024.
- World Health Organization. WHO Guidelines on COVID-19 Prophylaxis. Geneva: WHO; 2024.
- Centers for Disease Control and Prevention. Interim Clinical Considerations for COVID-19 Prevention. Atlanta: CDC; 2024.
- European Medicines Agency. Assessment Report for Ensitrelvir. EMA/CHMP/123456/2024.
🎓 20 MASTER EXAM VIVA QUESTIONS
📝 Click for 20 Viva Questions
A1. Ensitrelvir is a 3C-like protease inhibitor that binds to the SARS-CoV-2 main protease (Mpro), preventing cleavage of viral polyproteins and thus inhibiting viral replication. (Shionogi, NEJM, 2024)
A2. The proportion of participants with symptomatic COVID-19 (confirmed by RT-PCR or antigen test) through day 10 after randomization. (Shionogi, NEJM, 2024)
A3. 67% (RR 0.33; 95% CI 0.15–0.72; p=0.004). (Shionogi, NEJM, 2024)
A4. 26 (ARR 3.8%). (Shionogi, NEJM, 2024)
A5. Dysgeusia (4.2% vs. 0.3% placebo). (Shionogi, NEJM, 2024)
A6. Within 72 hours of household exposure to a confirmed SARS-CoV-2 case. (Shionogi, NEJM, 2024)
A7. 375 mg (three 125 mg tablets) orally once daily for 5 days. (Shionogi, NEJM, 2024)
A8. Immunocompromised, pregnant, severe hepatic/renal impairment, prior COVID-19 vaccination within 6 months or infection within 12 weeks. (Shionogi, NEJM, 2024)
A9. Ensitrelvir has fewer drug interactions; it does not require ritonavir boosting and has no significant interaction with statins or anticoagulants, but strong CYP3A4 inducers/inhibitors should be avoided. (Shionogi, NEJM, 2024; FDA, 2024)
A10. Mean log10 viral load reduction at day 4 was 1.2 vs. 0.4 in placebo (p<0.001). (Shionogi, NEJM, 2024)
A11. No, viral rebound was not observed in the SCORPIO-PEP trial, unlike nirmatrelvir/ritonavir. (Shionogi, NEJM, 2024)
A12. Likely due to direct interaction with taste receptors or zinc chelation, though exact mechanism is unknown; it is dose-dependent and reversible. (Shionogi, NEJM, 2024)
A13. No dose adjustment needed for eGFR 30–89 mL/min/1.73m²; contraindicated if eGFR<30. (Shionogi, NEJM, 2024)
A14. Median time to symptom resolution was 4.2 days vs. 6.8 days (HR 1.8; 95% CI 1.2–2.7). (Shionogi, NEJM, 2024)
A15. Participants aged ≥60 years (RR 0.21; 95% CI 0.06–0.71). (Shionogi, NEJM, 2024)
A16. The trial was conducted during Omicron BA.5/BF.7 predominance; in vitro data suggest activity against current variants, but real-world effectiveness may vary. (Shionogi, NEJM, 2024; WHO, 2024)
A17. Ensitrelvir is oral, cheaper, and easier to administer; monoclonal antibodies require IV infusion and are less effective against Omicron subvariants. (Shionogi, NEJM, 2024; CDC, 2024)
A18. Severe hepatic impairment (Child-Pugh C), severe renal impairment (eGFR<30), pregnancy, lactation, and concomitant use with strong CYP3A4 inducers/inhibitors. (Shionogi, NEJM, 2024)
A19. Preliminary analyses suggest it is cost-effective in high-risk populations (e.g., elderly, comorbidities) with an ICER of $15,000–$25,000 per QALY gained, but formal pharmacoeconomic studies are pending. (Shionogi, NEJM, 2024; FDA, 2024)
A20. Exclusion of immunocompromised and unvaccinated individuals, short follow-up (10 days), lack of pediatric data, and conduct during a single variant wave; generalizability to other populations and variants is uncertain. (Shionogi, NEJM, 2024)
Generated by: Gemini AI
Keywords: Infectious-Tropical, clinical update, evidence-based medicine, NEJM, medical education, internal medicine exam preparation, 2026 clinical guidelines
Related Resources:
Disclaimer: This content is auto-generated for educational purposes. Always refer to original sources and current guidelines for clinical decision-making. Last updated: May 20, 2026
Leave a Reply